Latest Breaking News On - Treat rev - Page 2 : comparemela.com

Share this article First-line indication offers Canadians with advanced lung cancer new treatment options TORONTO, March 17, 2021 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has issued ALUNBRIG ® (brigatinib tablets) marketing authorization without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). 1 The approval is based on results from the phase 3 ALTA-1L trial which evaluated 275 patients and showed that once-daily ALUNBRIG ® was superior to crizotinib on measures of efficacy and tolerability making it a promising first-line treatment option.

South koreaPopats brigatinibGeoffrey liuAmanda jacobsDavid fysheTakeda canada incBetter healthUniversity health networkPrincess margaret cancer care centreTakeda pharmaceutical company limitedTakeda pharmaceutical companyEastern cooperative oncology groupCanadian cancer societyHealth canadaPharmaceuticals incTakeda canada